Highest-materiality recent filing
Shalini Sharp elected with 33,732,317 votes for, 5,808,264 withheld, 1,969,475 broker non-votes.
Septerna reports Q1 net loss $8.6M; cash $522M; positive Phase 1 data for SEP-631
Revenue from Novo Nordisk collaboration $26.5M; net loss improved to $8.6M from $21.5M YoY.
Phase 1 SAD/MAD trial evaluating safety, tolerability, PK/PD in up to 150 healthy volunteers.
Septerna posts Q4 net loss $10.7M, highlights positive Phase 1 data for SEP-631
Phase 1 data: SEP-631 well-tolerated, once-daily oral dosing, complete wheal inhibition at 10 mg; Phase 2b in CSU planned H2 2026.
SEP-631 well-tolerated; adverse event profile comparable to placebo across all doses studied
Septerna at J.P. Morgan Healthcare Conference; no material news disclosed
Corporate presentation dated January 2026 furnished to SEC; no financial results or clinical updates included.
Septerna appoints Mark A. Wilson as Chief Legal Officer, effective January 8, 2026
Mark A. Wilson joins from Nektar Therapeutics, where he was SVP and Chief Legal Officer.
Septerna reports Q3 net income of $8.2M; cash at $561.6M into 2029; SEP-479 candidate selected
Q3 2025 net income $8.2M vs net loss $20.5M in Q3 2024; revenue $21.5M from Novo Nordisk collaboration.
Septerna appoints Keith Gottesdiener, M.D. to board as Class I director and R&D Committee chair
Appointment effective Sept 25; board expanded to eight; Gottesdiener serves three-year term until 2028.
Septerna updates corporate presentation for investor meetings; no material new data disclosed
Updated corporate presentation dated September 2025 for use with investors and analysts.
Septerna doses first participants in Phase 1 trial of SEP-631 for mast cell-driven diseases
SEP-631 is an oral small molecule MRGPRX2 negative allosteric modulator (NAM) targeting chronic spontaneous urticaria (CSU) and other mast cell-driven diseases.
Septerna Q2 net loss $24.8M; cash $379.2M; Novo Nordisk upfront $195M extends runway into 2029
Net loss of $24.8M for Q2 2025, up from $16.4M in Q2 2024; R&D expenses $22.2M, G&A $6.9M.
Septerna appoints COO Liz Bhatt as President effective Aug 1, 2025; CEO Finer remains
Liz Bhatt appointed President, effective Aug 1, 2025, while continuing as Chief Operating Officer.
Septerna and Novo Nordisk collaboration becomes effective after HSR clearance
Collaboration and License Agreement with Novo Nordisk became effective July 1, 2025.
Septerna stockholders elect two Class I directors and ratify auditor at annual meeting
Abraham Bassan and Alan Ezekowitz elected as Class I directors with ~29.3M and ~29.2M votes for, respectively.
Septerna reports Q1 net loss $21.5M, $398.2M cash; Novo Nordisk deal up to $2.2B
Collaboration with Novo Nordisk for oral small molecules in metabolic diseases: >$200M upfront and near-term, up to $2.2B total milestones plus royalties.
Septerna & Novo Nordisk partner on oral small molecule obesity drugs; upfront $195M, potential $2.2B
Collaboration covers up to 5 GPCR targets (GLP-1, GIP, glucagon) for oral small molecule therapies for obesity/T2D.
Septerna reports FY2024 net loss of $71.8M, discontinues SEP-786 Phase 1 trial
Discontinued SEP-786 Phase 1 trial after two Grade 3 elevated unconjugated bilirubin events, reversible without liver injury.
Septerna presents at TD Cowen conference; no material new disclosures in filing
Participated in TD Cowen 45th Annual Health Care Conference on March 3, 2025.
Septerna discontinues SEP-786 Phase 1 trial after bilirubin events; plans next-gen PTH1R agonist
Discontinued SEP-786 Phase 1 trial due to two Grade 3 unconjugated bilirubin events without ALT/AST elevation; no SAEs or liver injury.
Septerna presents at J.P. Morgan Healthcare Conference; no financial or pipeline updates in filing
Company is conducting meetings at the 43rd Annual J.P. Morgan Healthcare Conference in January 2025.
Septerna appoints Gil Labrucherie as CFO effective Jan 6, 2025; interim CFO Ran Xiao resigns
Gil Labrucherie appointed CFO, principal financial and accounting officer, effective Jan 6, 2025.
Septerna reports Q3 2024 net loss of $20.5M; cash runway into H2 2027 after IPO
Net loss of $20.5M for Q3 2024; R&D expenses $17.8M, G&A $4.9M.
Septerna amends charter and bylaws post-IPO, authorizes 500M common and 10M preferred shares
Authorized 500,000,000 shares of common stock and 10,000,000 shares of undesignated preferred stock.
On December 23, 2024, the Board of Directors (the “Board”) of Septerna, Inc. (the “Company”) appointed Gil M. Labrucherie as the Chief Financial Officer, principal financial officer and principal accounting officer of the Company, in each case, effective as of January 6, 2025.
Max materiality 0.90 · Median 0.55 · Most common event earnings